J. Jefferson Smith Sells 10,287 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the transaction, the insider now directly owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Precision BioSciences Stock Up 0.6 %

Precision BioSciences stock opened at $5.00 on Friday. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43. The business has a fifty day moving average price of $5.56 and a 200-day moving average price of $8.01. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The stock has a market capitalization of $38.35 million, a price-to-earnings ratio of 83.35 and a beta of 1.51.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday, January 10th. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research report on Friday, January 10th.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC grew its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.